3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Endocrine
1
CNS
1
Conditions
Carcinoma, Non-Small-Cell Lung
9
Lung Neoplasms
7
Breast Neoplasms
5
Glioma
4
Glioblastoma
4
Neoplasms
3
Gliosarcoma
3
Urinary Bladder Neoplasms
2
Stomach Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Pancreatic Neoplasms
2
Neoplasm Metastasis
2
Esophageal Neoplasms
2
Colorectal Neoplasms
2
Brain Neoplasms
2
Urethral Neoplasms
1
Ureteral Neoplasms
1
Unspecified Adult Solid Tumor, Protocol Specific
1
Thyroid cancer, medullary
1
Thyroid Neoplasms
1
Thyroid Diseases
1
Thyroid Cancer, Papillary
1
Small Cell Lung Carcinoma
1
Relapsed Pediatric Solid Tumor
1
Recurrence
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Precancerous Conditions
1
Pleural Effusion
1
Pheochromocytoma
1
Interventions
lutetium Lu 177 dotatate
29
Everolimus
19
Temozolomide
11
gallium Ga 68 dotatate
10
Nivolumab
10
Magnetic Resonance Spectroscopy
10
Capecitabine
9
pembrolizumab
8
lanreotide
8
Positron Emission Tomography Computed Tomography
8
cabozantinib
7
3-Iodobenzylguanidine
7
177Lu-octreotide, DOTA(0)-Tyr(3)-
7
Somatostatin
6
90Y-octreotide, DOTA-Tyr(3)-
6
telotristat ethyl
5
lenvatinib
5
Octreotide
5
Lutetium-177
5
Ga(III)-DOTATOC
5
Fluorodeoxyglucose F18
5
Carboplatin
5
avelumab
4
Positron-Emission Tomography
4
Ipilimumab
4
Bevacizumab
4
surufatinib
3
pasireotide
3
fluorodopa F 18
3
copper dotatate CU-64
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Neuroendocrine Tumors
×
vandetanib
×
Clear all
NCT01941849
2015-12-21
VIBRaNT
University College, London
Phase 1
Withdrawn